This is a preview of subscription content, log in via an institution to check access.
Notes
EuroQol-5 dimension-5 level
2018 British pounds
Reference
Jones DA, et al. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer 124: 178-185, 30 Nov 2019. Available from: URL: http://doi.org/10.1016/j.ejca.2019.10.025
Rights and permissions
About this article
Cite this article
Cisplatin cost effective for HPV-positive oropharyngeal cancer. PharmacoEcon Outcomes News 843, 9 (2019). https://doi.org/10.1007/s40274-019-6436-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6436-y